Is Tamoxifen Use a Factor Affecting Continence in Breast Cancer Patients?

Creative Commons License

Imamoglu G. I., eren t., Arzu O., ÖZDEMİR N., Karacin C., Baylan B.

Cureus, cilt.11, 2019 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11
  • Basım Tarihi: 2019
  • Doi Numarası: 10.7759/cureus.5417
  • Dergi Adı: Cureus
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Directory of Open Access Journals
  • Anahtar Kelimeler: breast cancer, tamoxifen, urinary incontinence, ENDOCRINE THERAPY, ADJUVANT TAMOXIFEN, SYMPTOMS, RALOXIFENE, URETHRA, WOMEN
  • Gazi Üniversitesi Adresli: Hayır

Özet

Introduction: Tamoxifen treatment has been shown to reduce the recurrence and mortality rates in hormone receptor-positive breast cancers independent from chemotherapy. This benefit increases with the prolongation of the use of tamoxifen but with increasing side effects. In this study, we aim to evaluate the presence of urogenital symptoms in breast cancer patients on tamoxifen and compare them with those who are not on any hormonotherapy.